(Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...
March 7 (Reuters) - The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.
Bayer ( OTCPK:BAYRY ) has filed for Japanese approval of Regeneron 's ( REGN ) Eylea therapy for treating patients with diabetic macular edema , the companies have said. Bayer has the rights to sell Eyelea outside
Xarelto (blood thinner) and Eylea (eye), which is developed by Regeneron ( REGN ), will hit peak revenues ..... holds the license to sell Eylea outside the U.S. Bayer ..... Xofigo (cancer), as well as Eylea and Xarelto - to at least
Stivarga and Xofigo (cancer), and Eylea (eye) - generated sales of €1.52B in ..... 5B. Bayer believes that Xarelto and Eylea will reach peak revenues in 5-6 years . Bayer holds the license to sell Eylea , which is developed by Regeneron , outside the U.S. Shares are +0
The FDA has accepted Regeneron 's ( REGN +3.3% ) application to expand the use of its Eylea therapy to treat Macular ..... away from the retina. Regeneron 's application follows ..... successful Phase III trial . Eylea has already been authorized
Regeneron 's ( REGN ) 7.4% gain topped today ..... s blockbuster-to-be, Eylea . Q4 U.S. sales of the ..... 46% Y/Y to $402M, and REGN forecasts U.S. sales to ..... uses. RBC Capital thinks Eylea sales could be better than
Regeneron Pharmaceuticals , Inc . ( REGN ) Q4 2013 Results Earnings Conference Call February 11, 2014 ..... Officer George D. Yancopoulos - Founding Scientist, President, Regeneron Laboratories and Chief Scientific Officer Robert J. Terifay
expected tax rate starting in 2017. Regeneron continues to make progress in expanding Eylea ’s label into additional indications ..... and increased R&D spending tied to Regeneron 's expansive clinical and research program, strong Eylea growth helped the firm increase its profit. Regeneron reported adjusted earnings per share
Regeneron ( REGN +2% ) net profit -79 ..... operating costs last year. Eylea net U.S. sales $402M vs ..... vs $588M. Forecasts 2014 Eylea net product sales of $1 ..... 1.41B in 2013. Expects Eylea to continue growing "through